ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 992

Differential Antigen-Presenting B-Cell Phenotype from Synovial Microenvironment of Rheumatoid Arthritis and Psoriatic Arthritis Patients

Estefania Armas-Gonzalez1, Ana Diaz-Martin1, María Jesús Dominguez-Luis2, Maria Teresa Arce-Franco1, Ada Herrera-Garcia1, Vanesa Hernandez1, Alicia Usategui3, Jose L. Pablos4, Juan D. Cañete5, Sagrario Bustabad1 and Federico Díaz-González1, 1Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 2Center of Biomedical Research of the Canary Islands, University of La Laguna, Tenerife, Spain, 3Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 4Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 5Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: antigen-presenting cells, B cells, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

The systemic depletion of B cells induced by mabthera, a monoclonal antibody against human CD20, has shown to be an effective therapy for controlling disease activity in rheumatoid arthritis (RA), but not in psoriatic arthritis (PsA) patients. This strongly suggests that B cells play a different role of in the pathogenesis of these diseases. It has been suggested that B cells participate in the pathogenesis of chronic synovitis through several mechanisms, including T-cell activation by acting as antigen-presenting cells. Objective: To study the potential differences in antigen-presenting phenotypes of B cells present in the synovial microenvironment of RA and PsA patients. 

Methods

The surface expression levels of CD27, CD23, class II molecules (HLA-DP, -DQ and -DR), CD40 and CD86 were assessed by double- or triple-staining flow cytometry on CD20+ cells from peripheral blood (PB) and synovial fluid (SF) of 13 RA and 15 PsA patients. Flow cytometry analysis data are presented as relative mean fluorescence intensity with respect to cells in PB, which was considered 100%. The expression of interferon-induced protein IFIT-4, which is involved in the differentiation of monocytes into dendritic cells, was assessed by quantitative RT-PCR in negatively immunoselected CD19+ B cells from SF and PB of RA patients.

Results

Analyzing all patients included in this study, the percentage of mononuclear CD20+ cells in SF (2.24±0.37%) was significantly lower than in PB (8.59±1.26%, p<0.01). When these data were compared in RA versus PsA patients, the percentages of CD20+ cells in PB and SF were similar in both range and tendency. B cells from SF of RA and PsA patients showed an activated phenotype (down-regulation of CD23) and seem to have had in contact with the antigen (up-regulation of CD27). Flow cytometry analyses showed an increased expression of HLA-DR and -DQ in CD20+ cells from SF compared to those from PB, in both RA (277.84±65.66; 262.20±108.81) and PsA (267.86±88.53; 311.08±116,65) patients. HLA-DP was also elevated in rheumatoid SF B cells (1009.48±335.70), although conversely, a significantly lower expression of this class II molecule was observed in SF from PsA patients (46.38±19.73). Surface expression of CD86 was higher in SF than in PB B cells from both pathologies (RA: 629.79±172.24; PsA: 326.46±138.77). CD40 expression was significantly lower in SF compared to PB in B cells from RA patients (66.31±12.21); however, this was not the case in PsA patients (243.76±71.18). Interestingly, CD20 surface expression was 35% lower in B cells (CD19+, CD138-) from SF with respect to PB in RA patients. Finally, qRT-PCR showed approximately a 5-fold increase in IFIT-4 mRNA content in B cells from SF compared to PB in RA patients. 

Conclusion

These data show that B cells in the synovial microenvironment of RA and PsA patients show a differential phenotype respect to molecules involved in antigen presentation and co-stimulation, which suggest that B cells play a different role in the pathogenesis of these two pathologies. This could have implications for the understanding of the dissimilar clinical response to B cell-depleting treatment observed in RA and PsA.


Disclosure:

E. Armas-Gonzalez,
None;

A. Diaz-Martin,
None;

M. J. Dominguez-Luis,
None;

M. T. Arce-Franco,
None;

A. Herrera-Garcia,
None;

V. Hernandez,
None;

A. Usategui,
None;

J. L. Pablos,
None;

J. D. Cañete,
None;

S. Bustabad,
None;

F. Díaz-González,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-antigen-presenting-b-cell-phenotype-from-synovial-microenvironment-of-rheumatoid-arthritis-and-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology